Frequency Therapeutics has always been really ambitious. My guess is as soon as they can get it to market, they will. Drugs can go to market during the Phase III trials, so we could see it as soon as late this year or early next year. But there are a lot of variables in play.
As for cost, they will want to maximize their profit. So what the final cost will be will depend on a number of things. One important thing will be if there's any competition. If Audion's LY3056480 drug fails, then FX-322 will be the only game in town and they'll be able to charge a lot. If LY3056480 is a big success, FX-322 will have to price their drug competitively. There are also other companies that have drugs in the pipeline, but for now it really looks like a race between LY3056480 and FX-322.
Last night I got a bill for a heart monitor I wore for 2 weeks. The bill was for $7,500, though insurance knocked it down so I only had to pay around $700. I was still pretty annoyed though. There has to be good competition for heart monitors, and mine was "mostly" covered by insurance. I fear a drug like FX-322 won't be covered as much (if at all - sort of like how laser eye surgery isn't typically covered by insurance).
At this point everything is speculation, but I would imagine a drug that could restore hearing and cure tinnitus costing around $10-20k. They may even charge by dose if it's discovered that additional doses help (maybe $5k per dose?).